<DOC>
	<DOCNO>NCT01471730</DOCNO>
	<brief_summary>Prospective , randomize , double blind trial . The rationale study concept fresh frozen plasma ( FFP ) still largely used cardiac surgery , despite fact prothrombin complex fibrinogen available.The experimental hypothesis cardiac surgery patient may operate use FFP coagulation factor replacement base fibrinogen prothrombin complex ( need ) . Primary endpoint : Transfusion avoidance Secondary endpoint : Transfusion limitation , massive blood transfusion , bleed . Study population : high-risk adult cardiac surgery patient Sample size : 2 group 60 patient</brief_summary>
	<brief_title>The ZEro PLASma Trial ( ZEPLAST ) : Avoidance Fresh Frozen Plasma Cardiac Surgery</brief_title>
	<detailed_description>Study design Randomized , placebo-controlled , double-blinded study Endpoints Primary : Transfusion avoidance every allogeneic blood product Secondary : Reduction number allogeneic blood product use , reduction massive blood transfusion event incidence , reduction postoperative bleeding . Patient population This study focus role coagulation factor substitute avoid transfusion . Therefore , patient population compose patient high-risk transfusion due bleed hemodilution . Moreover , bleed primarily due coagulation factor deficiency , rather cause ( namely , drug-induced platelet dysfunction ) . The major determinant coagulation factor consumption cardiac operation length CPB . Only patient undergo operation predictable CPB duration &gt; 90 minute admit . This include patient undergo complex cardiac operation ( double valve ; CABG+valve ; ascend aorta ; adult congenital patient ) . Adult congenital patient may particular interest , since usually preoperative reduce hepatic coagulation factor synthesis , due venous stasis polycythemia . To avoid effect hemodilution determine transfusional need , patient expect low HCT &lt; 23 % CPB admit study . This mean exclude patient preoperative HCT &lt; 35 % , patient small BSA ( &lt; 1.7 m2 ) . Hemodilution CPB check , case HCT value &lt; 23 % patient withdrawn study . Power analysis sample size Data Institutional database ( 15,000 patient ) retrieve accord report selection criterion . 1,535 patient ( 10 % ) fulfill randomization no-withdrawal criterion . Within group , could calculate follow outcome variable : Variable Incidence Mean SD Transfusion rate ( kind ) 61 % Packed red cell 57 % FFP 31 % Platelets 8 % Big bleeder ( &gt; 800 mL ) 20 % Postoperative bleeding 560±501 Surgical revision 5.7 % Based data , could perform power analysis base alpha value 0.05 beta value 0.20 . According value , require number patient enrol varies accord experimental hypothesis : Transfusion rate control group Hypothesis transfusion rate treatment group Number patient per group Total number patient 60 % 30 % 40 80 60 % 35 % 58 116 60 % 40 % 94 188 The study size 116 patient ( 58 per group ) . Study protocol Patients control group receive standard treatment available Hospital blood management hemostasis coagulation control . This include antifibrinolytic administration ( tranexamic acid 15 mg/kg CPB 15 mg/kg protamine ) Patients group transfuse accord standard protocol ( attachment 1 ) Randomization : seal envelope . Enveloped place pharmacy . Preparation drug vs. placebo dedicate biologist . Blinded vial send OR . Dosing protocol All patient randomize withdrawn test 20 minute removal aortic cross clamp thromboelastometry fibrinogen test FIBTEM ( Rotem ) . They receive either human fibrinogen concentrate ( accord formula : ( 22 [ mm ] − MCF [ mm ] ) * body weight [ kg ] / 140 [ ] = whole g fibrinogen dose HFC ) ( treatment group ) placebo ( control group ) . Study drug placebo administer protamine . After 15min study drug administration presence ongoing microvascular bleeding , run CT EXTEM . In case prolong CT time EXTEM long 80 second [ M1 ] , receive coagulation factor concentrate ( Confidex ) weight-based dose 7 U/kg b.w . ( treatment group ) placebo . In presence ongoing microvascular bleeding intraoperatively first 6 hour ICU , patient treat drug product control bleed accord standard protocol ( see `` Transfusion protocol '' ) . After dose , blood sample withdrawn , centrifuge , frozen plasma store subsequent Thrombin Generation Test . Blinding : An unblinded biologist follow drug randomization process , open seal envelope , drug preparation , ROTEM analysis . All Investigators blind . Transfusion protocol 1 . Definition bleeding : Intraoperatively : delay sterna closure due microvascular bleed Postoperatively : 2 mL/kg 2 consecutive hour ; 1.5 ml/kg 4 consecutive hour Packed red cell transfuse ( one unit time ) follow condition : 1 . Always Hb &lt; 7 g/dL 2 . Possible Hb 7 8 g/dL 3 . Possible medical justification ( hemodynamic instability ; high oxygen extraction rate ; sign organ ischemia… ) Hb 8 9 g/dL 4 . Never Hb ≥ 9 g/dL Fresh frozen plasma case bleed 1 . INR &gt; 1.5 2 . R time TEG ( heparinase ) &gt; 12 minute Platelets case bleed 1 . Platelet count &lt; 50.000/mmc 2 . Pre-treatment thienopyridinies ( applicable study ) In case intractable bleed determine hemodynamic instability , life-saving condition , mention condition may consider , empirical rescue therapy allow . Funding This study fund internally IRCCS Policlinico San Donato Research Fund . The drug ( fibrinogen concentrate PCC ) provide free charge CSL Behring , well reagent ROTEM analysis ,</detailed_description>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Thrombin</mesh_term>
	<criteria>The patient screen accord modify TRUST1 Transfusion Score . This score attribute 1 point follow condition : Hb level &lt; 13.5 g/dL Weight &lt; 77 kg Female sex Age &gt; 65 year Non elective surgery Serum creatinine &gt; 1.36 mg/dL Redo operation Non isolate surgery Factors hemodilutionrelated factor , include . Non isolate surgery mandatory inclusion . Patients include presence least 1 within remain 4 risk factor : Age &gt; 65 year Non elective surgery Serum creatinine &gt; 1.36 mg/dL '8Redo operation INCLUSION CRITERIA ( patient randomize ) 1 . Combined cardiac operation expect CPB duration &gt; 90 minute 2 . At least one additional risk factor within follow : Age &gt; 65 year ; Non elective surgery ; Serum creatinine &gt; 1.36 mg/dL ; Redo operation 1 . Age &lt; 18 year 2 . Patients thienopyridines 3 . Known coagulopathy 4 . Known autoimmune disorder 5 . Participation another RCT 6 . Pregnancy 7 . Emergency operation 8 . Baseline HCT &lt; 35 % 9 . Baseline Antithrombin &lt; 80 % 10 . BSA &lt; 1.7 m2 WITHDRAWAL CRITERION : 1 . Lowest HCT CPB &lt; 23 % 2 . Transfusions CPB Patients randomize withdrawn DOSED investigational drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Transfusions</keyword>
	<keyword>Fresh Frozen Plasma</keyword>
	<keyword>Fibrinogen</keyword>
	<keyword>Prothrombin complex</keyword>
</DOC>